Free tool
FAERS Monitor: Vibativ
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022407 or its brand name (Vibativ, Telavancin). Reports on generic versions are filed under their own applications.
Reports
120
Serious
91
76% of reports
Hospitalization
28
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use19
- renal failure acute15
- blood creatinine increased12
- nausea12
- chills9
- thrombocytopenia7
- diarrhoea6
- dyspnoea6
- leukopenia6
- renal failure6
- vomiting6
- acute kidney injury5
- rash5
- renal impairment5
- tubulointerstitial nephritis5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 2 |
| 2010 | 33 |
| 2011 | 45 |
| 2012 | 5 |
| 2014 | 4 |
| 2016 | 1 |
| 2018 | 23 |
| 2019 | 4 |
| 2025 | 1 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failure acuteSignal | 15 | 62.0 | 38.6 | 842 |
| tubulointerstitial nephritisSignal | 5 | 46.8 | 19.8 | 181 |
| blood creatinine increasedSignal | 12 | 32.2 | 18.8 | 333 |
| leukopeniaSignal | 6 | 21.0 | 9.6 | 96 |
| chillsSignal | 9 | 13.5 | 7.2 | 92 |
| thrombocytopeniaSignal | 7 | 11.0 | 5.3 | 54 |
| renal impairmentSignal | 5 | 10.4 | 4.4 | 34 |
| renal failureSignal | 6 | 7.9 | 3.6 | 30 |
| acute kidney injurySignal | 5 | 5.7 | 2.4 | 15 |
| off label useSignal | 19 | 3.8 | 2.5 | 38 |
| nauseaSignal | 12 | 2.7 | 1.6 | 11 |
| vomiting | 6 | 2.2 | 1.0 | 3 |
| rash | 5 | 2.0 | 0.9 | 2 |
| dyspnoea | 6 | 1.9 | 0.9 | 2 |
| diarrhoea | 6 | 1.6 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.